byinhibitingfatty-acid-bindingproteinaP2
Masato Furuhashi(Harvard University), S. Hotamisligil, Liza Makowski(University of Tennessee Health Science Center), Vladimir R. Babaev(Vanderbilt University Medical Center), Richard Sulsky(Bristol-Myers Squibb (Germany)), Sergio Fazio(Alzheimer's Association), MacRae F. Linton(Vanderbilt University), Rex A. Parker(Bristol-Myers Squibb (United States)), Gen‐ichi Atsumi(Teikyo University), Jeffrey A. Robl(Bristol-Myers Squibb (Germany)), Keita Kono(Harvard University), Eric Vaillancourt(Harvard University)
Unknown
January 1, 2007
Cited by 0
Related Papers
Current Perspectives on Statins
|Circulation|2000|1.2k
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
|Nature|2007|732
Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis
|Nature Medicine|2001|692